Nasal drugs show success in slowing Parkinson's disease progression in mice
Potential new treatments for Parkinson's disease developed by researchers at Rush University Medical Center have shown success in slowing progression of the disease in mice.
In a study published in Nature Communications, Rush researchers found that two different peptides (chains of amino acids) helped slow the spread of alpha-synuclein, a protein that occurs in abnormal protein deposits called Lewy bodies in the brain. Lewy bodies are hallmarks of Parkinson's disease, the most common movement disorder affecting about 1.2 million people in the United States and Canada.
"Currently, there are no treatments that slow the progression of Parkinson's disease -; they only treat the symptoms," says Kalipada Pahan, PhD, the Floyd A. Davis Professor of Neurology at Rush University Medical Center and a research career scientist at the Jesse Brown VA Medical Center, who led the study.
Lewy bodies are also associated with the development of Lewy body dementia and a rare neurological disorder called multiple system atrophy (MSA). "At present, there is also no effective treatment for dementia with Lewy bodies and multiple system atrophy," Pahan says. "Understanding how these diseases work is important to developing effective drugs that inhibit alpha-synuclein pathology, protect the brain, and stop the progression of Lewy body diseases."
The lab-developed peptides tested in the study are known as TLR2-interacting domain of Myd88 (TIDM) and NEMO-binding domain (NBD). The drugs, which were delivered through the nose, were found to slow inflammation in the brain and stop the spread of alpha-synuclein in mice with Parkinson's disease. The treatments also improved the mice's gait, balance, and other motor functions.
If these results can be replicated in patients, it would be a remarkable advance in the treatment of devastating neurological disorders."
Kalipada Pahan, PhD, Professor, Rush University Medical Center
Rush University Medical Center
Dutta, D., et al. (2021) Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo. Nature Communications. doi.org/10.1038/s41467-021-25767-1.
Posted in: Medical Science News | Medical Research News | Medical Condition News
Tags: Brain, Dementia, Drugs, Inflammation, Lewy Bodies, Movement Disorder, Multiple System Atrophy, Neurology, Parkinson's Disease, Pathology, Peptides, Protein, Research
Source: Read Full Article